FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024346310> ?p ?o ?g. }

• W2024346310 endingPage "10" @default.
• W2024346310 startingPage "4" @default.
• W2024346310 abstract "A multidisciplinary meeting addressed priorities related to development of vaccines against cytomegalovirus (CMV), the cause of congenital CMV (cCMV) disease and of serious disease in the immunocompromised. Participants discussed optimal uses of a CMV vaccine, aspects of clinical study design, and the value of additional research. A universal childhood CMV vaccine could potentially rapidly reduce cCMV disease, as infected children are sources of viral transmission to seronegative and seropositive mothers. A vaccine administered to adolescents or adult women could also reduce cCMV disease by making them immune prior to pregnancy. Clinical trials of CMV vaccines in women should evaluate protection against cCMV infection, an essential precursor of cCMV disease, which is a more practical and acceptable endpoint for assessing vaccine effects on maternal-fetal transmission. Clinical trials of vaccines to evaluate prevention of CMV disease in stem cell transplant recipients could use CMV viremia at a level triggering pre-emptive antiviral therapy as an endpoint, because widespread use of pre-emptive and prophylactic antivirals has rendered CMV-induced disease too rare to be a practical endpoint for clinical trials. In solid organ transplant patients, CMV-associated disease is sufficiently common for use as a primary endpoint. Additional research to advance CMV vaccine development should include identifying factors that predict fetal loss due to CMV, determining age-specific incidence and transmission rates, defining the mechanism and relative contributions of maternal reactivation and re-infection to cCMV disease, developing assays that can distinguish between reactivation and re-infection in seropositive vaccinees, further defining predictors of sequelae from cCMV infection, and identifying clinically relevant immune response parameters to CMV (including developing validated assays that could assess CMV antibody avidity) that could lead to the establishment of immune correlates of protection." @default.
• W2024346310 created "2016-06-24" @default.
• W2024346310 creator A5015407319 @default.
• W2024346310 creator A5017513685 @default.
• W2024346310 creator A5020844928 @default.
• W2024346310 creator A5027717859 @default.
• W2024346310 creator A5035976818 @default.
• W2024346310 creator A5054013231 @default.
• W2024346310 creator A5057743088 @default.
• W2024346310 creator A5079082437 @default.
• W2024346310 creator A5079512093 @default.
• W2024346310 creator A5079669354 @default.
• W2024346310 creator A5084900935 @default.
• W2024346310 date "2013-12-01" @default.
• W2024346310 modified "2023-10-10" @default.
• W2024346310 title "Priorities for CMV vaccine development" @default.
• W2024346310 cites W1515281699 @default.
• W2024346310 cites W1536477464 @default.
• W2024346310 cites W1564109452 @default.
• W2024346310 cites W162801203 @default.
• W2024346310 cites W1955863325 @default.
• W2024346310 cites W1965046421 @default.
• W2024346310 cites W1971742580 @default.
• W2024346310 cites W1973646541 @default.
• W2024346310 cites W1983781028 @default.
• W2024346310 cites W1985024339 @default.
• W2024346310 cites W1986822882 @default.
• W2024346310 cites W1992168621 @default.
• W2024346310 cites W1996960673 @default.
• W2024346310 cites W2020381478 @default.
• W2024346310 cites W2025711278 @default.
• W2024346310 cites W2040478749 @default.
• W2024346310 cites W2044887490 @default.
• W2024346310 cites W2052546898 @default.
• W2024346310 cites W2053161235 @default.
• W2024346310 cites W2056774192 @default.
• W2024346310 cites W2059471557 @default.
• W2024346310 cites W2064288175 @default.
• W2024346310 cites W2072986862 @default.
• W2024346310 cites W2076646013 @default.
• W2024346310 cites W2086734706 @default.
• W2024346310 cites W2095200251 @default.
• W2024346310 cites W2102507699 @default.
• W2024346310 cites W2102850108 @default.
• W2024346310 cites W2105193766 @default.
• W2024346310 cites W2106940179 @default.
• W2024346310 cites W2116687125 @default.
• W2024346310 cites W2117134638 @default.
• W2024346310 cites W2119962983 @default.
• W2024346310 cites W2132990407 @default.
• W2024346310 cites W2133963802 @default.
• W2024346310 cites W2136389983 @default.
• W2024346310 cites W2136632163 @default.
• W2024346310 cites W2137079103 @default.
• W2024346310 cites W2145301696 @default.
• W2024346310 cites W2154418144 @default.
• W2024346310 cites W2156604614 @default.
• W2024346310 cites W2156763025 @default.
• W2024346310 cites W2156766489 @default.
• W2024346310 cites W2159541449 @default.
• W2024346310 cites W2164200647 @default.
• W2024346310 cites W2165012523 @default.
• W2024346310 cites W2171944774 @default.
• W2024346310 cites W2315098267 @default.
• W2024346310 cites W2315851568 @default.
• W2024346310 cites W2616662114 @default.
• W2024346310 cites W4211083670 @default.
• W2024346310 doi "https://doi.org/10.1016/j.vaccine.2013.09.042" @default.
• W2024346310 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4623576" @default.
• W2024346310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24129123" @default.
• W2024346310 hasPublicationYear "2013" @default.
• W2024346310 type Work @default.
• W2024346310 sameAs 2024346310 @default.
• W2024346310 citedByCount "121" @default.
• W2024346310 countsByYear W20243463102014 @default.
• W2024346310 countsByYear W20243463102015 @default.
• W2024346310 countsByYear W20243463102016 @default.
• W2024346310 countsByYear W20243463102017 @default.
• W2024346310 countsByYear W20243463102018 @default.
• W2024346310 countsByYear W20243463102019 @default.
• W2024346310 countsByYear W20243463102020 @default.
• W2024346310 countsByYear W20243463102021 @default.
• W2024346310 countsByYear W20243463102022 @default.
• W2024346310 countsByYear W20243463102023 @default.
• W2024346310 crossrefType "journal-article" @default.
• W2024346310 hasAuthorship W2024346310A5015407319 @default.
• W2024346310 hasAuthorship W2024346310A5017513685 @default.
• W2024346310 hasAuthorship W2024346310A5020844928 @default.
• W2024346310 hasAuthorship W2024346310A5027717859 @default.
• W2024346310 hasAuthorship W2024346310A5035976818 @default.
• W2024346310 hasAuthorship W2024346310A5054013231 @default.
• W2024346310 hasAuthorship W2024346310A5057743088 @default.
• W2024346310 hasAuthorship W2024346310A5079082437 @default.
• W2024346310 hasAuthorship W2024346310A5079512093 @default.
• W2024346310 hasAuthorship W2024346310A5079669354 @default.
• W2024346310 hasAuthorship W2024346310A5084900935 @default.
• W2024346310 hasBestOaLocation W20243463102 @default.
• W2024346310 hasConcept C119599485 @default.

• next